Journals / Haseki Tıp Bülteni / 2022 / Cilt: 60 - Sayı: 3

Investigation of Cardiovascular Disease and Metabolic Syndrome Risk with Copeptin in Psoriasis Patients: A Case-Control Study

Pages
270–275
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Psoriasis patients should be followed up with easily accessible parameters such as neutrophil-lymphocyte rate, thrombocyte-lymphocyte rate, insulin levels, FBG, and uric acid levels.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: Psoriasis is thought to result in vascular diseases, atherogenesis, peripheral insulin resistance, and cardiac comorbidities by causing metabolic function disorders, hypertension, and type 2 diabetes.
📊
Key Findings & Data:Methods: The presented case-control study, which is a type of analytical observational study, included 45 psoriasis patients and an age-sex matched control group admitted to University of Health Sciences Turkey, Istanbul Haseki Training and Research Hospital, Clinic of Dermatology, between March 2016 and May 2017.
💡
Conclusion & Impact:Psoriasis patients should be followed up with easily accessible parameters such as neutrophil-lymphocyte rate, thrombocyte-lymphocyte rate, insulin levels, FBG, and uric acid levels.
🔬Design:Research Article
📍Scope:2016 Verileri
⚙️Variables:Domain Parameters

Abstract

Aim: Psoriasis is thought to result in vascular diseases, atherogenesis, peripheral insulin resistance, and cardiac comorbidities by causing metabolic function disorders, hypertension, and type 2 diabetes. To our best knowledge, there has not yet been a study evaluating psoriasis patients with regard to copeptin. The present study assesses cardiovascular disease in psoriasis patients based on metabolic function and copeptin levels. Methods: The presented case-control study, which is a type of analytical observational study, included 45 psoriasis patients and an age-sex matched control group admitted to University of Health Sciences Turkey, Istanbul Haseki Training and Research Hospital, Clinic of Dermatology, between March 2016 and May 2017. Patients’ blood pressure, height, weight, body mass index, and waistline were measured for both groups. All subjects were also given complete blood count, fasting blood glucose (FBG), uric acid, lipid profile, insulin, C-reactive protein (CRP), copeptin levels, neutrophil-lymphocyte rate, and thrombocyte-lymphocyte rate were analysed. Copeptin was measured by an ELISA kit. Results: Insulin and CRP averages were statistically significantly higher in psoriasis patients than in the control group (p=0.001 for both). The neutrophil-lymphocyte and thrombocyte-lymphocyte rates were significantly higher in psoriasis patients (p=0.008). Insulin resistance was also higher in psoriasis patients (p=0.001). In both the patient and control groups, there was no statistically significant relationship found between copeptin level, general characteristics, and laboratory parameters. Conclusion: To our best knowledge, this is the first study evaluating psoriasis patients with regard to copeptin. Psoriasis patients should be followed up with easily accessible parameters such as neutrophil-lymphocyte rate, thrombocyte-lymphocyte rate, insulin levels, FBG, and uric acid levels.

🔖

Cite This Article

GÜMÜŞ, A., AĞIRGÖ, M., ÇAKIR, E., ÇAYTEMEL, C., DEMİR, F. T., AKBULUT, T. Ö., AĞIRGÖL, S., TÜRKOĞLU, Z. (2022). Investigation of Cardiovascular Disease and Metabolic Syndrome Risk with Copeptin in Psoriasis Patients: A Case-Control Study. Haseki Tıp Bülteni, Cilt: 60 - Sayı: 3, 270–275. https://ajindex.com/articles/534949

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Walter K. Psoriasis. JAMA 2022;327:1936
  2. Piros EA, Szilveszter B, Vattay B, et al. Novel anti-inflammatory therapies to reduce cardiovascular burden of psoriasis. Dermatol Ther 2021;34:e14721
  3. Tollefson MM, Van Houten HK, Asante D, Yao X, Maradit Kremers H. Association of Psoriasis With Comorbidity Development in Children With Psoriasis. JAMA Dermatol 2018; 10.1001/jamadermatol.2017.5417
  4. Gisondi P, Fostini AC, Fossa I, Girolomoni G, Targher G. Psoriasis and the metabolic syndrome. Clin Dermatol 2018;36:21-8
  5. Lai YC, Yew YW. Psoriasis as an Independent Risk Factor for Cardiovascular Disease: An Epidemiologic Analysis Using a National Database. J Cutan Med Surg 2016;20:327-33
  6. Borsky P, Fiala Z, Andrys C, et al. C-reactive protein, chemerin, fetuin-A and osteopontin as predictors of cardiovascular risks in persons with psoriasis vulgaris. Physiol Res 2021;70:383- 91
  7. Egeberg A, Khalid U, Gislason GH, Mallbris L, Skov L, Hansen PR. Impact of Depression on Risk of Myocardial Infarction, Stroke and Cardiovascular Death in Patients with Psoriasis: A Danish Nationwide Study. Acta Derm Venereol 2016;96:218- 21
  8. Christophers E. Psoriasis--epidemiology and clinical spectrum. Clin Exp Dermatol 2001;26:314-20
  9. Bolignano D, Cabassi A, Fiaccadori E, et al. Copeptin (CTproAVP), a new tool for understanding the role of vasopressin in pathophysiology. Clin Chem Lab Med 2014;52:1447-456
  10. Canivell S, Mohaupt M, Ackermann D, et al. Copeptin and insulin resistance: effect modification by age and 11 beta- HSD2 activity in a population-based study. J Endocrinol Invest 2017; 10.1007/s40618-017-0807-7
  11. Baranowska B, Kochanowski J. Copeptin - a new diagnostic and prognostic biomarker in neurological and cardiovascular diseases. Neuro Endocrinol Lett 2019;40:207-14
  12. Wang J, Tan GJ, Han LN, Bai YY, He M, Liu HB. Novel biomarkers for cardiovascular risk prediction. J Geriatr Cardiol 2017;14:135-50
  13. El Dayem SMA, Battah AA, El Bohy AEM, Yousef RN, Talaat A. Copeptin as a Biomarker of Atherosclerosis in Type 1 Diabetic Patients. Open Access Maced J Med Sci 2019;7:3975-978
  14. Yamazaki F. Psoriasis: Comorbidities. J Dermatol 2021;48:732- 40
  15. Ryan C, Menter A. Psoriasis and cardiovascular disorders. G Ital Dermatol Venereol 2012;147:179-87
  16. Wakkee M, Herings RM, Nijsten T. Psoriasis may not be an independent risk factor for acute ischemic heart disease hospitalizations: results of a large population-based Dutch cohort. J Invest Dermatol